Drug Profile
SYGN 305
Alternative Names: SYGN-305Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Synedgen
- Class Anti-inflammatories; Polysaccharides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Graft-versus-host disease; Mucositis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA
- 28 Nov 2020 No recent reports of development identified for preclinical development in Mucositis in USA
- 15 Jan 2020 Synedgen has patent protection for SYGN 305 in Europe, USA, Australia, Canada and Japan